CL2013003306A1 - Uso de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, un tautómero o sal de la misma para preparar un medicamento útil para el tratamiento de carcinoma adenoide quístico. - Google Patents

Uso de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, un tautómero o sal de la misma para preparar un medicamento útil para el tratamiento de carcinoma adenoide quístico.

Info

Publication number: CL2013003306A1
Authority: CL; Chile
Prior art keywords: benzimidazol; quinolin; tautomer; piperazin; fluoro
Prior art date: 2011-05-19

Application number

CL2013003306A

Other languages

English (en)

Inventor

Michael Shi

Michael Wick

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-05-19

Filing date

2013-11-18

Publication date

2014-07-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46168643&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013003306(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-11-18 Application filed by Novartis Ag filed Critical Novartis Ag

2014-07-11 Publication of CL2013003306A1 publication Critical patent/CL2013003306A1/es

Links

208000002517 adenoid cystic carcinoma Diseases 0.000 title 1
PIQCTGMSNWUMAF-UHFFFAOYSA-N chembl522892 Chemical compound C1CN(C)CCN1C1=CC=C(NC(=N2)C=3C(NC4=CC=CC(F)=C4C=3N)=O)C2=C1 PIQCTGMSNWUMAF-UHFFFAOYSA-N 0.000 title 1
239000003814 drug Substances 0.000 title 1
229940079593 drug Drugs 0.000 title 1
201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 title 1
150000003839 salts Chemical class 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

CL2013003306A 2011-05-19 2013-11-18 Uso de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, un tautómero o sal de la misma para preparar un medicamento útil para el tratamiento de carcinoma adenoide quístico. CL2013003306A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201161487939P	2011-05-19	2011-05-19

Publications (1)

Publication Number	Publication Date
CL2013003306A1 true CL2013003306A1 (es)	2014-07-11

Family

ID=46168643

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2013003306A CL2013003306A1 (es)	2011-05-19	2013-11-18	Uso de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, un tautómero o sal de la misma para preparar un medicamento útil para el tratamiento de carcinoma adenoide quístico.

Country Status (18)

Country	Link
US (1)	US20150182525A1 (es)
EP (1)	EP2709729A1 (es)
JP (1)	JP2014515353A (es)
KR (1)	KR20140023358A (es)
CN (1)	CN103547315A (es)
AU (1)	AU2012255148A1 (es)
BR (1)	BR112013029246A2 (es)
CA (1)	CA2834699A1 (es)
CL (1)	CL2013003306A1 (es)
IL (1)	IL229073A0 (es)
MA (1)	MA35156B1 (es)
MX (1)	MX2013013437A (es)
PH (1)	PH12013502099A1 (es)
RU (1)	RU2013156378A (es)
SG (1)	SG194445A1 (es)
TN (1)	TN2013000414A1 (es)
WO (1)	WO2012158994A1 (es)
ZA (1)	ZA201307411B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2012088266A2 (en)	2010-12-22	2012-06-28	Incyte Corporation	Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
HRP20170430T1 (hr)	2012-06-13	2017-06-16	Incyte Holdings Corporation	Supstituirani triciklični spojevi kao inhibitori fgfr
WO2014026125A1 (en)	2012-08-10	2014-02-13	Incyte Corporation	Pyrazine derivatives as fgfr inhibitors
EA201791717A1 (ru)	2012-09-07	2018-03-30	Кохерус Байосайенсис, Инк.	Стабильные водные составы адалимумаба
US9266892B2 (en)	2012-12-19	2016-02-23	Incyte Holdings Corporation	Fused pyrazoles as FGFR inhibitors
PL2986610T4 (pl)	2013-04-19	2019-06-28	Incyte Holdings Corporation	Bicykliczne heterocykle jako inhibitory FGFR
US10851105B2 (en)	2014-10-22	2020-12-01	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
MY197720A (en)	2015-02-20	2023-07-10	Incyte Corp	Bicyclic heterocycles as fgfr inhibitors
WO2016134294A1 (en)	2015-02-20	2016-08-25	Incyte Corporation	Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr)	2015-02-20	2017-12-26	Incyte Corp	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US11229702B1 (en)	2015-10-28	2022-01-25	Coherus Biosciences, Inc.	High concentration formulations of adalimumab
US9782370B2 (en) *	2015-12-21	2017-10-10	Gongwin Biopharm Holdings Co., Ltd.	Pharmaceutical compositions of benzenesulfonamide derivatives for treatment of adenoid cystic carcinoma
US11071782B2 (en)	2016-04-20	2021-07-27	Coherus Biosciences, Inc.	Method of filling a container with no headspace
AR111960A1 (es)	2017-05-26	2019-09-04	Incyte Corp	Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
BR112020022392A2 (pt)	2018-05-04	2021-02-02	Incyte Corporation	formas sólidas de um inibidor de fgfr e processos para preparação das mesmas
JP7568512B2 (ja)	2018-05-04	2024-10-16	インサイト・コーポレイション	Ｆｇｆｒ阻害剤の塩
US11628162B2 (en)	2019-03-08	2023-04-18	Incyte Corporation	Methods of treating cancer with an FGFR inhibitor
WO2021007269A1 (en)	2019-07-09	2021-01-14	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
US12122767B2 (en)	2019-10-01	2024-10-22	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
JP7675711B2 (ja)	2019-10-14	2025-05-13	インサイト・コーポレイション	Ｆｇｆｒ阻害剤としての二環式複素環
WO2021076728A1 (en)	2019-10-16	2021-04-22	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
PE20221504A1 (es)	2019-12-04	2022-09-30	Incyte Corp	Derivados de un inhibidor de fgfr
CA3163875A1 (en)	2019-12-04	2021-06-10	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
WO2021146424A1 (en)	2020-01-15	2021-07-22	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
US12115140B2 (en) *	2020-07-31	2024-10-15	The Trustees Of Columbia University In The City Of New York	Method of treating adenoid cystic carcinoma
WO2022221170A1 (en)	2021-04-12	2022-10-20	Incyte Corporation	Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
EP4352060A1 (en)	2021-06-09	2024-04-17	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
AR126102A1 (es)	2021-06-09	2023-09-13	Incyte Corp	Heterociclos tricíclicos como inhibidores de fgfr

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU9327501A (en)	2000-09-11	2002-03-26	Chiron Corp	Quinolinone derivatives
BR0313743A (pt)	2002-08-23	2005-07-05	Chiron Corp	Benzimidazol quinolinonas e usos destas
DK1845990T3 (da) *	2005-01-27	2012-01-02	Novartis Vaccines & Diagnostic	Behandling af metastaserede tumorer
JP5344910B2 (ja) *	2005-05-13	2013-11-20	ノバルティスアーゲー	薬剤耐性癌の処置方法
EP2266974A1 (en)	2005-05-23	2010-12-29	Novartis AG	Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-Quinolin-2-one lactic acid salts
ATE450615T1 (de)	2005-07-22	2009-12-15	Five Prime Therapeutics Inc	Zusammensetzungen und verfahren zur behandlung von krankheiten mit fgfr-fusionsproteinen
PE20091628A1 (es)	2008-03-19	2009-11-19	Novartis Ag	Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona
RU2012148706A (ru) *	2010-04-16	2014-05-27	Новартис Аг	Комбинация органичемких соединений

2012
- 2012-05-18 BR BR112013029246A patent/BR112013029246A2/pt not_active IP Right Cessation
- 2012-05-18 MX MX2013013437A patent/MX2013013437A/es unknown
- 2012-05-18 SG SG2013075270A patent/SG194445A1/en unknown
- 2012-05-18 CN CN201280023953.9A patent/CN103547315A/zh active Pending
- 2012-05-18 EP EP12723801.2A patent/EP2709729A1/en not_active Withdrawn
- 2012-05-18 AU AU2012255148A patent/AU2012255148A1/en not_active Abandoned
- 2012-05-18 PH PH1/2013/502099A patent/PH12013502099A1/en unknown
- 2012-05-18 US US14/117,057 patent/US20150182525A1/en not_active Abandoned
- 2012-05-18 RU RU2013156378/15A patent/RU2013156378A/ru unknown
- 2012-05-18 WO PCT/US2012/038490 patent/WO2012158994A1/en not_active Ceased
- 2012-05-18 JP JP2014511568A patent/JP2014515353A/ja active Pending
- 2012-05-18 CA CA2834699A patent/CA2834699A1/en not_active Abandoned
- 2012-05-18 KR KR1020137030212A patent/KR20140023358A/ko not_active Withdrawn
2013
- 2013-10-04 ZA ZA2013/07411A patent/ZA201307411B/en unknown
- 2013-10-11 TN TNP2013000414A patent/TN2013000414A1/fr unknown
- 2013-10-24 IL IL229073A patent/IL229073A0/en unknown
- 2013-11-15 MA MA36443A patent/MA35156B1/fr unknown
- 2013-11-18 CL CL2013003306A patent/CL2013003306A1/es unknown

Also Published As

Publication number	Publication date
ZA201307411B (en)	2014-06-25
TN2013000414A1 (en)	2015-03-30
NZ616345A (en)	2015-10-30
RU2013156378A (ru)	2015-06-27
EP2709729A1 (en)	2014-03-26
MX2013013437A (es)	2013-12-06
SG194445A1 (en)	2013-12-30
MA35156B1 (fr)	2014-06-02
JP2014515353A (ja)	2014-06-30
AU2012255148A1 (en)	2013-11-07
CN103547315A (zh)	2014-01-29
PH12013502099A1 (en)	2017-10-25
IL229073A0 (en)	2013-12-31
US20150182525A1 (en)	2015-07-02
KR20140023358A (ko)	2014-02-26
BR112013029246A2 (pt)	2017-02-14
CA2834699A1 (en)	2012-11-22
WO2012158994A1 (en)	2012-11-22

Similar Documents

Publication	Publication Date	Title
CL2013003306A1 (es)	2014-07-11	Uso de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, un tautómero o sal de la misma para preparar un medicamento útil para el tratamiento de carcinoma adenoide quístico.
NO2025022I1 (no)	2025-05-12	Belzutifan, or a pharmaceutically acceptable salt thereof, particularly belzutifan.
BR112015003376A2 (pt)	2017-07-04	composto ou sal farmaceuticamente aceitável do mesmo , composição farmacêutica e usos de quantidade eficiente
IL235607A0 (en)	2015-01-29	Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
LT3447061T (lt)	2022-01-25	Farmacinė vaisto forma, apimanti 5-fluor-2'-deoksiuridinofosforamidato darinį, skirtą naudoti vėžio gydymui
BR112015003397A2 (pt)	2019-09-24	composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente.
CL2014002873A1 (es)	2015-04-24	Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
LT3026064T (lt)	2019-01-25	Antikūnai, skirti vėžio gydymui, ekspresuojantys klaudiną 6
BR112015002524A2 (pt)	2017-07-04	derivados de alquilpirimidina para o tratamento de infecções virais e outras doenças.
PL3871515T3 (pl)	2025-06-16	Sole nikotyny, ko-kryształy i kompleksy ko-kryształów soli
CL2014001988A1 (es)	2014-11-03	Un compuesto 5-(4-ciclopropil-1h-imidazol-1-il)-n-(6-(4-isopropil-4h-1,2,4-triazol-3-il)piridin-2-il)-2-fluoro-4-metilbenzamida o sus sales, como inhibidores de la quinasa reguladora de la señal de apoptosis; compuestos intermediarios; composicion farmaceutica; y su uso para el tratamiento de la enfermedad renal cronica, nefropatia diabetica, fibrosis renal, entre otras.
BR112014028424A2 (pt)	2018-04-24	compostos de pirimidina para o tratamento de câncer
PT2838539T (pt)	2017-11-15	Derivados estrogénicos para utilização no tratamento de distúrbios neurológicos.
BR212014030074U2 (pt)	2017-06-13	segmento de filtro para um artigo para fumar , artigo para fumar.
LT2945642T (lt)	2024-06-25	Faktoriaus 1 baltymas, skirtas naudoti ligų gydymui arba prevencijai
SI3069720T1 (sl)	2020-02-28	Farmacevtski sestavek, ki vsebuje derivate glutarimida, in njegova uporaba za zdravljenje eozinofilnih bolezni
PL2872497T3 (pl)	2017-07-31	Pochodne chromanylowe do leczenia choroby mitochondrialnej
BR112014031635A2 (pt)	2017-06-27	derivados de pró-fármaco de (e)-n-metil-n-( (3-metilbenzofuran-2-il) metil)-3-(7-oxo-5,6,7,8-tetraidro- 1, 8- naftirindin-3-il) acrilamida
CL2013003230A1 (es)	2014-08-01	Uso de volasertib, una sal o un hidrato del mismo para preparar un medicamento útil en el tratamiento de tumores sólidos avanzados y/o metastásicos.
BR112014030159A2 (pt)	2017-06-27	agente para tratamento de floculação.
BR112014027814A2 (pt)	2017-06-27	agentes sinérgicos antimicrobianos.
LTPA2020511I1 (lt)	2020-07-27	Ciklezonidas, skirtas arklių kvėpavimo takų ligų gydymui
CL2013003198A1 (es)	2014-06-20	Uso de volasertib, una sal o un hidrato del mismo para preparar un medicamento útil en el tratamiento de malignidades sólidas que incluyen malignidades sólidas avanzadas y metastásicas.
BR302012006416S1 (pt)	2014-06-03	Configuração aplicada em traquéia para dispositivos de inalação.
BR112014027953A2 (pt)	2018-02-06	nifuratel- (r), seu uso para o tratamento de infecções e síntese de nifuratel -(r) e -(s)